盐酸安罗替尼联合吉西他滨+顺铂对晚期NSCLC患者T淋巴细胞亚群及肿瘤标志物水平的影响
Effect of anlotinib hydrochloride combined with gemcitabine plus cisplatin on T lymphocyte subsets and tumor marker levels in patients with advanced NSCLC
刘勇 1叶亮 1邵小霞1
作者信息
- 1. 乐平市人民医院肿瘤内科,江西 景德镇 333300
- 折叠
摘要
目的:观察盐酸安罗替尼联合吉西他滨+顺铂(GP)化疗对晚期非小细胞肺癌(NSCLC)患者T淋巴细胞亚群以及肿瘤标志物水平的影响.方法:选取 2021 年 10 月至2023 年 10 月于本院进行治疗的晚期NSCLC患者 60例,随机分成对照组与研究组,各 30 例,对照组采用GP方案治疗,研究组采用盐酸安罗替尼联合GP方案治疗,观察比较两组患者的疗效、T淋巴细胞亚群与肿瘤标志物的水平.结果:研究组疾病控制率显著高于对照组(P＜0.05).治疗后,两组患者CD3+水平均较治疗前有明显提升,研究组的CD4+、CD4+/CD8+较治疗前明显提升,CD8+显著下降,对照组较治疗前无明显变化,两组差异显著(P＜0.05).治疗后,两组癌胚抗原(CEA)、角蛋白 19 片段抗原 21-1(CYFRA21-1)水平均显著降低,研究组相较于对照组更低(P＜0.05).结论:盐酸安罗替尼联合GP方案治疗晚期NSCLC患者疗效更好,能更有效的调节机体T淋巴细胞亚群水平与肿瘤标志物水平.
Abstract
Objective:To observe the effect of anlotinib hydrochloride combined with gemcitabine plus cisplatin(GP)chemotherapy on T lymphocyte subsets and tumor marker levels in patients with advanced non-small cell lung cancer(NSCLC).Methods:Sixty patients with advanced NSCLC treated in the hospital from October 2021 to October 2023 were selected,and randomly grouped.The control group(n=30)was treated with GP regimen,while the study group(n=30)was treated with anlotinib hydrochloride combined with GP regimen.Therapeutic effects,T lymphocyte subsets,and tumor marker levels in the two groups were observed and compared.Results:Compared with control group,the disease control rate was significantly higher in study group(P<0.05).After treatment,CD3+levels in both groups increased significantly.There were significant increases in CD4+and CD4+/CD8+levels,and a significant decrease in CD8+level in study group.However,there was no significant change in the control group.The differences between groups were significant(P<0.05).After treatment,the levels of CEA and CYFRA21-1 in both groups decreased significantly,with the levels were lower in study group(P<0.05).Conclusion:Anlotinib hydrochloride combined with GP regimen is more effective in the treatment of patients with advanced NSCLC.It can regulate the levels of T lymphocyte subsets and tumor markers in patients more significantly.
关键词
晚期非小细胞肺癌/盐酸安罗替尼/吉西他滨+顺铂/T淋巴细胞亚群/肿瘤标志物Key words
Advanced non-small cell lung cancer/Anlotinib hydrochloride/Gemcitabine plus cisplatin/T lymphocyte subset/Tumor marker引用本文复制引用
出版年
2024
NETL
NSTL
万方数据